


RESEARCH ARTICLE

Open Access



# Effectiveness of letters to patients with or without Cochrane blogshots on 10-year cardiovascular risk change among women in menopausal transition: 6-month three-arm randomized controlled trial

Slavica Jurić Petričević<sup>1</sup>, Ivan Buljan<sup>2</sup>, Dora Bjelanović<sup>3</sup>, Nataša Mrduljaš-Đujić<sup>4</sup>, Tanja Pekez<sup>5</sup>, Mario Ćurković<sup>6,7</sup>, Željko Vojvodić<sup>7,8</sup>, Ivančica Pavličević<sup>4</sup>, Matko Marušić<sup>9</sup> and Ana Marušić<sup>2\*</sup> 

## Abstract

**Background:** Health information and patient education on lifestyle changes may have a positive effect on the prevention of many chronic conditions, especially cardiovascular diseases (CVDs). We performed a parallel, three-arm randomized controlled trial (RCT) of 6-month educational intervention in a form of letters containing a reminder of the participant's CVD risk with or without Cochrane blogshots to reduce CVD risk among women aged 45–65 with one or more known CVD risk factors.

**Methods:** The control group received a letter about their CVD risk at the beginning of the trial. The intervention groups received the initial letter about their CVD risk and remainder letters about their CVD risk every 2 months, with or without Cochrane blogshots: (1) effect of calcium in the prevention of high blood pressure, (2) effect of reducing saturated fat acids in eating habits, and (3) effects of green and black tea in CVD prevention. The primary outcome was CVD risk reduction calculated as the difference between the baseline and 6-month score for a 10-year risk of fatal CVD according to the ACC/AHA guidelines.

**Results:** After both interventions, CVD risk reduction was significantly higher compared to the control group ( $P < 0.001$ , Kruskal-Wallis  $H$  test). The number of participants who decreased their CV risk was 29% (20/70) in the control group, 69% (48/70) in the group receiving the reminder letters, and 70% (49/70) in the group receiving the reminder letters and blogshots. The number needed to treat to achieve risk reduction was 2.41 (95% CI = 1.77 to 3.78) for letters with a CVD risk reminder and 2.50 (1.81 to 4.03) for letters with a reminder and a blogshot. The group receiving reminder letters with Cochrane blogshots had a significant change in the category of CVD risk, mainly from high to moderate and from moderate to low CVD risk category.

**Conclusions:** A simple and inexpensive intervention method in a form of letters reminding women about their CVD risk with or without providing additional health information in the form of Cochrane blogshots about interventions

\*Correspondence: ana.marusic@mefst.hr

<sup>2</sup> Department of Research in Biomedicine and Health and Center for Evidence-based Medicine, University of Split School of Medicine, Šoltanska 2, Split, Croatia

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

for important CVD risk factors may be effective in CVD management and could be considered by primary care providers.

**Trial registration:** ClinicalTrials.gov, NCT04601558. Retrospectively registered on October 19, 2020

**Keywords:** Cochrane blogshots, Educational intervention, CVD risk, Women

## Background

Translation of health information to the patients is an important aspect of educational interventions in health care. One of the highly respected and high-quality sources of information for both the doctors and the patients is summaries of evidence synthesis—scientific abstracts and plain language abstracts, respectively, such as those produced by Cochrane. We have previously shown that plain language summaries of Cochrane systematic reviews increase knowledge of patients about health issues that is comparable to infographics of the same abstract [1]. Shortened versions of plain language summaries of Cochrane systematic reviews in the form of single-slide brief and focused information (blogshots) seem to be even more effective than plain language summaries in terms of change in comprehension of health information among patients/consumers [1].

An area where the translation of best evidence to the patients/consumers is important is chronic diseases, such as cardiovascular diseases (CVDs). They are the leading cause of morbidity and mortality worldwide, so the prevention of CVDs remains high on the agenda of any health care system [2, 3]. The focus is on the primary prevention of CVD: identifying and treating risk factors, including hypertension, dyslipidemia, diabetes, smoking, obesity, and physical inactivity [4]. Due to the misperception that females are “protected” against CVD, the risk of CVD in women is often underestimated [5]. The lack of awareness by women about their CVD risks represents a challenge to effective and timely patient management [6]. Several studies have shown that women receive suboptimal CVD preventive care, and gender disparities in recommendations for preventive therapy have been largely explained by the lower perceived danger of CVD risk in women despite the similar calculated risk for women versus men [7].

Lifestyle change programs have a beneficial effect on recurrent cardiovascular events because CVD is strongly associated with lifestyle, especially tobacco use, unhealthy dietary habits, physical inactivity, and psychosocial stress [8]. Recent studies have shown that patient education can contribute to changing behavior and improving compliance with the prescribed preventive and therapeutic measures [9, 10]. These educational interventions include clinical decision support, education, patient-involvement strategies, telephone and email

support follow-up [11, 12], mobile health technology [13], and nurse-led educational intervention [14], significantly improving knowledge, drug adherence, and quality of life in patients with CVD.

To test the effectiveness of providing a summary of the best evidence for interventions for CVD risk in reducing CVD risk among women in menopausal transition who have one or more known cardiovascular risk factors, we performed a parallel, three-arm randomized controlled trial (RCT) in a 6-month educational intervention in a form of letters containing a reminder of the participant's 10-year CVD risk with or without Cochrane blogshots about interventions directed to some CVD risk factors.

## Methods

### Trial design

This parallel, three-arm randomized controlled trial (RCT) tested the effect of a 6-month educational intervention in a form of letters in decreasing the 10-year CVD risk in women aged 45 to 65 with one or more known CVD risk factors. The letters reminded the participants of their own 10-year CVD risk, with or without included Cochrane blogshots.

### Participants

The inclusion criteria were (1) female sex; (2) age 45 to 65 years, which is the age of menopause transition, including postmenopause [15]; and (3) one or more CVD risk factors: overweight or obesity (body mass index (BMI)  $\geq 25$  kg/m<sup>2</sup>, and/or central obesity, i.e., waist circumference  $\geq 88$  cm), high blood pressure (systolic blood pressure  $\geq 140$  mmHg and/or diastolic blood pressure  $\geq 90$  mmHg), high blood cholesterol ( $\geq 5.2$  mmol/L), and active smoking. The participants on antihypertensive therapy were eligible for the study.

Current CVD (ischemic heart disease, peripheral artery disease, and stroke), malignant diseases, serious systemic diseases, and/or mental diseases were the exclusion criteria.

The trial took place in family medicine offices in Croatia from February 1, 2018, to September 1, 2020. Family medicine offices are primary health care offices, i.e., the first step for patients to seek help for their health problems in the Croatian health care system, which ensures full national health coverage. Physicians working in family medicine offices are specialists in family medicine.

One office was in the city of Split, the capital of the Split-Dalmatia County; one in the city of Osijek, the capital of the Osijek-Baranja County; and one in the city of Rijeka, the capital of the Primorje-Gorski Kotar County. An office from each of the following towns was the recruitment sites: Supetar (the island of Brač, Split-Dalmatia County), Bijelo Brdo (Vukovar-Srijem County), Kotoriba (Međimurje County), and Kutina (Sisak-Moslavina County). In each family medicine office, 30 participants were recruited. All participants involved in this trial had access to their family medicine office according to their place of residence. The first participant was recruited in February 2018, and the last participant was recruited in February 2020. The recruitment was performed by family medicine doctors in their medical offices. They also performed clinical measurements at the baseline and 6 months after the intervention, after sending the notification to the participants about their check-up appointment. The data from the two time points were sent to the primary investigator.

The Ethics Committee of the University of Split, School of Medicine, approved the study, No. 2181-198-03-94/10-11-0038 and No. 2181-198-03-04/19-0044. Written informed consent was obtained from all participants after they received the information about the study. The data were processed as pseudonymized (coded) data, following the General Data Protection Regulation (GDPR).

### Intervention

The participants were randomized into three parallel groups:

1. Control group: A month after recruitment, the participants received a letter that included the list of their own CVD risk factors and their 10-year risk of CVD, based on the data provided by the participants during recruitment. This was the only letter this group received.
2. Passive intervention group: The participants first received a letter with the same information as the control group. After this letter, the participants received a letter every 2 months, which reminded them of their own CVD risk factors and their 10-year risk of CVD. In total, this group received four letters at their home address during the trial.
3. Active intervention group: The participant first received the same letter as the other two groups. Every 2 months after that letter, they received a reminder about their own CVD risk factors and their 10-year risk of CVD, together with a Cochrane systematic review summary in the form of a blogshot. The topics in the blogshots were the following: (1) the effect of calcium in the prevention of high blood

pressure [16], (2) the effect of reducing saturated fat acids in eating habits [17], and (3) the effects of green and black tea in the prevention of CVD [18]. In total, this group received four letters at their home address during the trial.

The examples of all types of letters sent to the participants in each group (in Croatian) are available in Additional file 1: Letters 1–5, including the Cochrane blogshots (in Croatian) used in the letters.

### Outcomes

At recruitment and at 6 months after the intervention, we measured the following clinical parameters: height, weight, BMI, waist and hips circumference, systolic and diastolic blood pressure, total serum cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol, triglycerides, and glucose.

The primary outcome measure was the change in the score between the 10-year risk of CVD at the beginning of the study and the 10-year risk of CVD after 6 months. The 10-year risk of fatal CVD was estimated using an online tool (<https://www.cvriskcalculator.com/>) based on the American College of Cardiology/American Heart Association (ACC/AHA) guidance [19]. The calculation is based on the following data collected from the study participants: age, gender, race, total and HDL cholesterol, systolic blood pressure, data about antihypertensive therapy, diabetes mellitus, and smoking status. The 10-year risk of fatal CVD was expressed as a percentage and was calculated at the beginning of the trial and at 6 months, after the participants received the last letter.

The secondary outcome measures were the changes in weight (in kg), body mass index (BMI), waist circumference (in cm), hip circumference (in cm), and smoking status (related to continued or excessive smoking) at 6 months post-intervention. The number of participants who changed their CVD risk category—low, moderate, and high [19]—was also calculated.

After recruitment, the participants first completed the pre-study questionnaire (in Croatian), which included (a) demographic data (available in Additional file 2), (b) Decisional Conflict Scale (DCS) [20–22], and (c) future time perspective (FTP) [23].

The DCS consists of 16 items rated on a 5-point Likert scale and measures an individual's uncertainty toward a course of action. The score is calculated as a sum of items, divided by the number of items and multiplied by 25, allowing for a score range from 0 (no decisional conflict) to 100 points (extreme decisional conflict) [20, 21]. The Croatian version of the scale was previously validated [22].

The FTP is a 13-item scale from the Time Perspective Inventory [23]. It assesses how respondents focus on planning and achievement of future goals. The respondent answers using a 5-point Likert scale from 1 (does not refer to me) to 5 (refers to me completely), maximum score of 65. Higher scores indicate a greater future time perspective.

### Sample size

As there were no previous studies on this topic, we hypothesized that in the intervention group at the end of the trial, the mean CVD risk would be 6.0 and 8.0 in the control group, with a standard deviation of 3. With a study strength of 0.8 and alpha level of 0.01 (to take multiple comparisons into account), we used an online sample size calculator (<https://epitools.ausvet.com.au/twomeansone>), to estimate that we would need at least 53 participants per group (159 in total). To compensate for potential dropouts, we aimed to recruit 70 participants per trial arm.

### Randomization and blinding

Trial groups were formed by a random assignment, so that each respondent had one probability of falling into one of the three research groups (1:1:1) and each group of participants was exposed to only one of the study interventions. The generation of the random sequence was performed by a statistician who was not involved in the conduct of the trial, using <https://www.randomizer.org/>. Only the main investigator was aware of the allocation of participants into the study groups, and the participants, the family medicine doctors, or the statistician were not aware of the allocation of participants to trial arms. The family medicine doctors made physical exams and took all measurements of each eligible participant. The main investigator prepared all letters, sealed them in opaque envelopes, and sent them to the addresses collected from the medical records of the participants.

### Statistical analysis

Categorical data are presented as frequencies and percentages. Numerical variables did not follow a normal distribution and were presented as medians with IQR or with 95% confidence intervals (CIs). Due to the asymmetrical distribution of the variables, a parametric  $2 \times 2$  factorial analysis could not be performed. As there is no non-parametric analog, the post-intervention differences between the three groups were compared by using the Kruskal-Wallis test with post hoc Conover-Iman test. To address multiple comparisons, we applied the Bonferroni correction to avoid type I error. The differences in CVD risk were made by subtracting the scores at the end of the trial with the ones from the baseline assessment,

which sometimes resulted in negative scores. The results were expressed as a median difference in the score (with 95% CI). The changes in the number of participants who changed the category of their 10-year CVD risk after the interventions were tested using the McNemar  $\chi^2$  test. The risk ratios and numbers needed to treat (NNTs) were calculated based on the number of participants who had a decrease in CVD risk after the interventions. We used linear regression to determine the variables that predicted the pre- and post-assessment changes. The results were expressed as unstandardized coefficients and  $R^2$ . All analyses were performed by the R programming software (R Core Team, 2021).


### Trial registration

The trial was retrospectively registered on [ClinicalTrials.gov](https://clinicaltrials.gov) on October 19, 2020 (trial registration number NCT04601558). The trial was retrospectively registered because of the lack of timely official access to the registry by the first author from the University Hospital of Split.

### Results

In total, 210 participants took part in the study (70 per group) with a median age of 58 years (IQR 52–62) (Fig. 1). There were no dropouts or missing data points in all groups. The majority of the participants had at least a high school education and were employed, married, and in postmenopausal reproductive status. Almost 90% of the participants gave birth at least once (Table 1). The majority of the participants had been prescribed antihypertensive therapy, and obesity, arterial hypertension, and high cholesterol were the most prevalent types of CVD risk (Table 1). Patients from all groups had a rather low decisional conflict and high future time perspective, regardless of the group (Table 1).

The median differences between the post- and pre-intervention CVD risk scores were greater for both intervention groups in comparison with the control group (Table 2). While the women in the control group had an increase in their post-intervention CVD risk (median difference = 0.55, 95% CI = 0.2 to 1.0), the group receiving reminder letters only or with Cochrane blogshots decreased their CVD risk (median difference = -0.6%, 95% CI = -1.0 to -0.2 and median difference = 0.9%, 95% CI = -1.5 to -0.4, respectively). The results of the Kruskal-Wallis  $H$  test showed that there was a statistically significant difference between the three groups ( $\chi^2_2 = 31.0$ ,  $P < 0.001$ , with a mean rank score of 138.3 for the control group, 92.8 for the group receiving letters with reminders about their 10-year CVD risk, and 85.4 for the group receiving reminders and Cochrane blogshots). The Conover post hoc test comparison showed that the



control group significantly differed from the other two groups, which did not differ between themselves.

The change in the CVD risk was the result of significant changes in weight, hip circumference, and blood pressure, where the same differences were observed as for the change in CVD risk (Table 2, Additional file 3: Table S1).

The number of participants who decreased their CV risk was 29% (20/70) in the control group, 69% (48/70) in the group receiving the reminder letters, and 70%

(49/70) in the group receiving the reminder letters and blogshots. The risk ratio for the CVD risk decrease after intervention between the active intervention (reminder letters and blogshots) and control groups was 0.41 (95% CI = 0.27 to 0.61), and NNT was 2.41 (95% CI = 1.77 to 3.78). The risk ratio between the passive intervention (reminder letters only) and control groups was 0.42 (0.28 to 0.63), and NNT was 2.50 (1.81 to 4.03).

**Table 1** Demographic characteristics (n (%)) of the trial participants

| Variable  | Overall (n = 210)   | Control (n = 70)    | Letters with CVD risk reminder (n = 70) | Letters with CVD risk reminder and Cochrane blogshot (n = 70) |
|---|---------------------|---------------------|---|---|
| Age (median, IQR)                                     | 58 (52 to 62)       | 58 (54 to 61)       | 59 (53 to 62)                           | 58 (52 to 62)   |
| Educational level                                     |                     |                     |   |   |
| Elementary school                                     | 45 (21.4)           | 17 (24.3)           | 15 (21.4)                               | 13 (18.6)   |
| High school   | 127 (60.5)          | 40 (57.1)           | 47 (67.1)                               | 40 (57.1)   |
| College   | 16 (7.6)            | 8 (11.4)            | 4 (5.7)                                 | 4 (5.7)   |
| University  | 22 (10.5)           | 5 (7.1)             | 4 (5.7)                                 | 13 (18.6)   |
| Work status   |                     |                     |   |   |
| Employed  | 101 (48.1)          | 26 (37.1)           | 34 (48.6)                               | 41 (58.6)   |
| Unemployed  | 52 (24.7)           | 23 (32.9)           | 18 (25.7)                               | 11 (15.7)   |
| Retired   | 57 (27.1)           | 21 (30.0)           | 18 (25.7)                               | 18 (25.7)   |
| Marital status  |                     |                     |   |   |
| Married   | 154 (73.3)          | 49 (70.0)           | 55 (78.6)                               | 50 (71.4)   |
| Not married   | 15 (7.1)            | 5 (7.1)             | 3 (4.3)                                 | 7 (10.0)  |
| Divorced  | 17 (8.1)            | 6 (8.6)             | 4 (5.7)                                 | 7 (10.0)  |
| Widowed   | 24 (11.4)           | 10 (14.3)           | 8 (11.4)                                | 6 (8.6)   |
| Reproductive status                                   |                     |                     |   |   |
| Premenopausal status                                  | 42 (20.0)           | 17 (24.3)           | 13 (18.6)                               | 12 (17.1)   |
| Perimenopausal status                                 | 14 (6.7)            | 6 (8.6)             | 5 (7.1)                                 | 3 (4.3)   |
| Postmenopausal  | 154 (73.3)          | 47 (67.1)           | 52 (74.3)                               | 55 (78.6)   |
| Childbirths   |                     |                     |   |   |
| No  | 22 (10.5)           | 8 (11.4)            | 5 (7.1)                                 | 9 (12.9)  |
| One   | 32 (15.2)           | 13 (18.6)           | 10 (14.3)                               | 9 (12.9)  |
| Two   | 112 (53.3)          | 37 (52.9)           | 38 (54.3)                               | 37 (52.9)   |
| Three or more   | 44 (21.0)           | 12 (17.1)           | 17 (24.3)                               | 15 (21.4)   |
| Antihypertensive therapy (yes)                        | 145 (69.0)          | 43 (61.4)           | 55 (78.6)                               | 47 (67.1)   |
| Diabetes (yes)  | 30 (14.3)           | 8 (11.4)            | 14 (20.0)                               | 8 (11.4)  |
| Smoking (yes)   | 69 (32.9)           | 25 (35.7)           | 18 (25.7)                               | 26 (37.1)   |
| Type of cardiovascular risk                           |                     |                     |   |   |
| Overweight  | 158 (75.2)          | 50 (71.4)           | 56 (80.0)                               | 52 (74.3)   |
| Diabetes  | 29 (13.8)           | 8 (11.4)            | 12 (17.1)                               | 9 (12.9)  |
| Arterial hypertension                                 | 149 (71.0)          | 43 (61.4)           | 58 (82.9)                               | 48 (68.6)   |
| High cholesterol                                      | 167 (79.5)          | 53 (75.7)           | 54 (77.1)                               | 60 (85.7)   |
| Sedentary lifestyle                                   | 86 (40.9)           | 24 (34.3)           | 28 (40.0)                               | 34 (48.6)   |
| Unhealthy eating habits                               | 105 (50.0)          | 37 (52.9)           | 35 (50.0)                               | 33 (47.1)   |
| Smoking   | 66 (31.4)           | 25 (35.7)           | 16 (22.9)                               | 25 (35.7)   |
| 10-year CVD risk score <sup>a</sup> (% , median, IQR) | 5.2 (3.1 to 8.9)    | 5.1 (2.8 to 7.3)    | 6.1 (3.7 to 10.3)                       | 5.0 (3.0 to 8.9)  |
| Decisional conflict score (median, IQR) <sup>b</sup>  | 25.8 (17.1 to 34.3) | 25.0 (17.1 to 34.3) | 28.1 (22.2 to 39.0)                     | 25.0 (15.6 to 31.2)   |
| Informed subscale                                     | 25.0 (25.0 to 25.0) | 25.0 (25.0 to 33.0) | 33.3 (25.0 to 33.3)                     | 25.0 (25.0 to 25.0)   |
| Values clarity subscale                               | 25.0 (25.0 to 25.0) | 25.0 (16.6 to 25.0) | 25.0 (25.0 to 25.0)                     | 25.0 (16.6 to 25.0)   |
| Support subscale                                      | 25.0 (25.0 to 25.0) | 25.0 (25.0 to 33.0) | 25.0 (25.0 to 33.0)                     | 25.0 (16.6 to 25.0)   |
| Uncertainty subscale                                  | 25.0 (25.0 to 33.0) | 25.0 (25.0 to 33.0) | 33.3 (25.0 to 41.6)                     | 25.0 (16.6 to 25.0)   |
| Effective decision subscale                           | 25.0 (25.0 to 25.0) | 25.0 (25.0 to 25.0) | 25.0 (25.0 to 31.2)                     | 25.0 (18.7 to 25.0)   |
| Future time perspective (median, IQR) <sup>c</sup>    | 50.5 (45.0 to 55.0) | 51.0 (45.0 to 55.0) | 49.0 (45.0 to 54.0)                     | 51.0 (46.3 to 56.0)   |

IQR interquartile range, CVD cardiovascular risk, ACC/AHH American College of Cardiology/American Heart Association

<sup>a</sup> According to ACC/AHH guidelines [19], <https://www.cvriskcalculator.com/>

<sup>b</sup> Decisional Conflict Scale (DCS), score range 0 (no decisional conflict) to 100 points (extreme decisional conflict) [21]

<sup>c</sup> Future Time Perspective Scale, score range from 13 (low) to 65 (high future time perspective)

**Table 2** Pre-post intervention differences in cardiovascular (CVD) risk-related variables (median difference, 95% confidence interval) before and after interventions

|                              | Overall (n = 210)    | Control (n = 70) | Letters with CVD risk reminder (n = 70) | Letters with CVD risk reminder and Cochrane blogshots (n = 70) | P <sup>a</sup>                |
|------------------------------|----------------------|------------------|---|--|-------------------------------|
| Weight (kg)                  | 0 (0 to 0)           | 1 (0 to 2)       | 0 (− 2 to 3)                            | 0 (− 3 to 0)   | <b>0.002<sup>b</sup></b>      |
| Body mass index              | 0 (0 to 0)           | 0.2 (0.0 to 0.8) | 0.0 (− 0.8 to 0.0)                      | 0.0 (1.1 to 0.0)   | 0.004                         |
| Waist circumference (cm)     | 0 (− 1 to 0)         | 0 (0 to 1)       | 0 (0 to 0)                              | − 2 (− 2 to 0)   | 0.085                         |
| Hip circumference (cm)       | 0 (0 to 0)           | 0 (0 to 2)       | − 1 (− 2 to 0)                          | − 1 (− 2 to 0)   | <b>&lt; 0.001<sup>c</sup></b> |
| Systolic pressure (mmHg)     | 0 (0–0)              | 5 (0 to 5)       | 0 (− 10 to 0)                           | − 5 (− 13 to − 8)  | <b>&lt; 0.001<sup>d</sup></b> |
| Diastolic pressure (mmHg)    | 0 (− 5 to 0)         | 0 (− 5 to 0)     | 0 (− 5 to 0)                            | 0 (− 5 to 0)   | 0.286                         |
| Total cholesterol (mmol/L)   | 0 (0–0)              | 0.2 (0.0 to 0.3) | 0.0 (− 0.4 to 0.0)                      | − 0.1 (− 0.3 to 0.1)   | 0.130                         |
| HDL cholesterol (mmol/L)     | 0.0 (0.0 to 0.1)     | 0 (0 to 0)       | 0.0 (0.0 to 0.1)                        | 0.1 (0.0 to 0.2)   | 0.013                         |
| Non-HDL cholesterol (mmol/L) | 0.0 (− 0.2 to 0.1)   | 0.2 (0.0 to 0.3) | − 0.3 (− 0.4 to 0.0)                    | − 0.3 (− 0.4 to 0.2)   | 0.008                         |
| LDL cholesterol (mmol/L)     | 0 (0 to 0)           | 0 (0 to 0)       | 0 (0 to 0)                              | 0 (0 to 0)   | NA                            |
| Triglycerides (mmol/L)       | 0 (0 to 0)           | 0 (0 to 0)       | 0 (0 to 0)                              | 0 (0 to 0)   | NA                            |
| Glucose (mmol/L)             | 0 (0 to 0)           | 0 (0 to 0)       | 0 (0 to 0)                              | 0 (0 to 0)   | NA                            |
| 10-year CVD risk (%)         | − 0.2 (− 0.4 to 0.0) | 0.5 (0.2 to 1.0) | − 0.6 (− 1.0 to − 0.2)                  | − 0.9 (− 1.5 to − 0.4)   | <b>&lt; 0.001<sup>e</sup></b> |

<sup>a</sup> Kruskal-Wallis *H* test with Conover post hoc comparison. The Bonferroni correction was applied, and *P* value level was set at  $\alpha = 0.05/15 = 0.003$

<sup>b</sup>  $\chi^2_2 = 19.4, P < 0.001$ ; a mean rank score of 126.4 for the control group, 97.2 for the group receiving letters with the reminder about their 10-year CVD risk, and 92.9 for the group receiving reminder letters and Cochrane blogshots. Conover post hoc comparison: control group vs two intervention groups

<sup>c</sup>  $\chi^2_2 = 16.0, P < 0.001$ ; a mean rank score of 129.1 for the control group, 91.4 for the group receiving letters with reminders about their 10-year CVD risk, and 95.9 for the group receiving reminder letters and Cochrane blogshots. Conover post hoc comparison: control group vs two intervention groups

<sup>d</sup>  $\chi^2_2 = 19.4, P < 0.001$ ; a mean rank score of 131.6 for the control group, 92.5 for the group receiving letters with reminders about their 10-year CVD risk, and 92.4 for the group receiving reminder letters and Cochrane blogshots. Conover post hoc comparison: control group vs two intervention groups

<sup>e</sup> CVD risk was calculated according to the ACC/AHH guidelines [19], <https://www.cvriskcalculator.com/>. Kruskal-Wallis *H* test:  $\chi^2_2 = 31.0, P < 0.001$ ; a mean rank score of 138.3 for the control group, 92.8 for the group receiving letters with the reminder about their 10-year CVD risk, and 85.4 for the group receiving reminder letters and Cochrane blogshots. Conover post hoc comparison: control group vs two intervention groups

We also assessed the changes in the category of the 10-year CVD risk. In the control group and the group that received the reminder letters, there were no significant changes in the categories at baseline and post-intervention assessment (Additional file 3: Table S1). In the group receiving the reminder letters with Cochrane blogshots, there were significant changes in their CVD risk category (McNemar  $\chi^2$  test,  $\chi^2_3 = 8.77, P = 0.032$ , Additional file 3: Table S1): out of 22 participants who had high risk at baseline, 7 changed to the moderate and 2 to the low CVD risk category. Out of 13 participants who had moderate CVD risk at baseline, 8 changed to the low and 1 to the high CVD risk category. In the group of participants with low baseline CVD risk ( $n = 35$ ), 3 changed to the moderate and none to the high CVD risk category after the intervention.

In the linear regression analysis that included all pre-intervention measurements except CVD risk, the model explained 48.9% of the variance, but the only significant variable which predicted the pre-post difference in CVD risk score was the higher result on the *Effective decision* subscale of the Decisional Conflict Scale (Table 3). However, when entered as the only predictor in a new model, the predictor strength of the *Effective decision* subscale was 0.28 (standard error, SE = 0.12), explaining only 2.7%

of the variance. Finally, when linear regression models with the *Effective decision* subscale as the only predictor of CVD risk difference were built for each trial group, it was significant only in the passive intervention group ( $B = 0.06, SE = 0.02, R^2 = 0.08$ ).

## Discussion

This randomized controlled trial showed that a simple intervention in the form of letters reminding patients about their 10-year CVD risk was an effective measure in family practice management of increased CVD risk. After receiving three written reminders from their family medicine doctor’s office every 2 months, women with one or more known CVD risk factors significantly decreased those risks. Both the letters with a simple reminder about their CVD risk and letters with Cochrane blogshots in addition to the reminder were successful interventions. Letters including Cochrane blogshots had greater odds for a greater reduction in the CVD risk.

## Strengths and limitations

The strengths of our study include a simple, inexpensive, and non-invasive assessment of CVD risk factors, a high rate of participant adherence, and the parallel, three-arm randomized controlled study design which

**Table 3** Linear regression of predictors of greater post-intervention difference in cardiovascular disease (CVD) risk before and after the interventions

| Variable  | Level                     | Unstandardized | Standard error | P     |
|---|---------------------------|----------------|----------------|-------|
| (Intercept)   |                           | − 36.985       | 69.776         | 0.599 |
| Age in years  |                           | − 0.044        | 0.144          | 0.762 |
| Educational level                                       | Ref: elementary school    |                |                |       |
|   | High school               | − 2.806        | 1.404          | 0.052 |
|   | College                   | 1.312          | 1.082          | 0.232 |
|   | University                | 1.618          | 2.043          | 0.433 |
| Work status   | Ref: employed             |                |                |       |
|   | Unemployed                | − 1.367        | 0.781          | 0.088 |
|   | Retired                   | 0.543          | 1.134          | 0.635 |
| Marital status  | Ref: married              |                |                |       |
|   | Not married               | − 0.604        | 1.069          | 0.575 |
|   | Divorced                  | 1.581          | 2.413          | 0.516 |
|   | Widowed                   | 1.279          | 1.614          | 0.433 |
| Reproductive status                                     | Ref: premenopausal status |                |                |       |
|   | Perimenopausal status     | 0.45           | 1.041          | 0.668 |
|   | Postmenopausal            | 1.009          | 1.261          | 0.428 |
| Childbirths   | Ref: no                   |                |                |       |
|   | One                       | − 0.636        | 2.243          | 0.778 |
|   | Two                       | 0.404          | 1.125          | 0.721 |
|   | Three or more             | 1.229          | 1.179          | 0.304 |
| Height (cm)   |                           | 0.219          | 0.423          | 0.607 |
| Weight (kg)   |                           | − 0.366        | 0.442          | 0.413 |
| BMI   |                           | 0.923          | 1.160          | 0.431 |
| Waist circumference (cm)                                |                           | 0.083          | 0.085          | 0.334 |
| Hip circumference (cm)                                  |                           | − 0.045        | 0.084          | 0.599 |
| HDL cholesterol (mmol/L)                                |                           | 1.746          | 1.675          | 0.303 |
| LDL cholesterol I (mmol/L)                              |                           | − 0.396        | 0.627          | 0.531 |
| Glucoses (mmol/L)                                       |                           | − 0.544        | 0.535          | 0.315 |
| Number of cigarettes per day                            |                           | 0.122          | 0.084          | 0.152 |
| Decisional conflict: <i>Informed</i> subscale           |                           | 0.031          | 0.049          | 0.528 |
| Decisional conflict: <i>Values clarity</i> subscale     |                           | − 0.092        | 0.053          | 0.091 |
| Decisional conflict: <i>Support</i> subscale            |                           | 0.046          | 0.029          | 0.120 |
| Decisional conflict: <i>Uncertainty</i> subscale        |                           | − 0.049        | 0.047          | 0.302 |
| Decisional conflict: <i>Effective decision</i> subscale |                           | 0.103          | 0.039          | 0.012 |

reduces the chance of confounding. Furthermore, the study provides a strong piece of evidence of the usefulness of providing CVD risk information and ways to decrease it as a simple and cost-effective method in shared-decision making. The strength of the study is also the use of the ACC/AHA guidelines to calculate CVD risk, based on a full set of data collected from the study participants (age, gender, race, total and high-density lipoprotein (HDL) cholesterol, systolic blood pressure, data about antihypertensive therapy, diabetes mellitus, and smoking status) [19]. Previous studies have indicated that more individuals are recommended

for the treatment according to the ACC/AHA guidelines than to other guidelines [24].

The main limitation of the study is its short-term nature. We cannot make conclusions whether the intervention would have long-term effects. We also tested only Cochrane blogshots as the simplest way of presenting the evidence synthesis about health interventions. Our study was not specifically designed to differentiate the effects of Cochrane blogshots over CVD risk reminders, and further studies are needed to investigate the separate effects of blogshots over risk reminders. We included women of specific age, from 45 to 65



years, in order to cover the full menopause transition from premenopause, menopause, and early postmenopause, which is the period for increased CVD risk for women [15]. This means that other reproductive outcomes associated with an increased CVD risk could not be evaluated, such as pre-eclampsia, hypertensive disorders of pregnancy, and gestational diabetes mellitus [15]. Finally, the study was performed in a single country in a health system that is publicly funded, provides universal health care coverage, and has family medicine as the basic point of primary health care. We balanced the geographical, cultural, and economic differences among family medicine settings by including family medicine offices from 6 different country regions, including southern coastal and island trials sites and northern sites, as well as sites in major cities and smaller towns.

### Interpretation

The results from our trial suggest that a simple and inexpensive intervention method in a form of letters reminding patients about their CVD risk, especially when accompanied by health information in the form of Cochrane blogshots about interventions for important CVD risk factors, can play an important role in CVD management. Cardiovascular risk decreased significantly in the intervention groups compared to the control group. The intervention in the form of Cochrane blogshots—short textual information about a systematic review on a simple graphic template—has been shown to have a positive effect on the comprehension of health information among different users [1]. It is possible that other forms of presenting health information about interventions for CVD risk factor would be more effective than blogshots, especially those containing more detailed information about the results of Cochrane systematic reviews. There are several arguments against this hypothesis. First, we showed that the readability of plain language summaries of Cochrane systematic reviews is low, almost twice that of the recommended reading level for health information [25]. Secondly, in randomized trials, Cochrane infographic summaries did not produce a better understanding compared to lay summaries among different users—health consumers, doctors, and medical students, although users had greater preference for visual information [26]. Finally, we also showed in a randomized trial that blogshots were better than plain language summaries in increasing understanding of health information and had higher preference among all users—health consumers, doctors, and medical students [1]. The findings from this study suggest that a simple information such as a reminder of CVD risk sent at regular intervals is a useful intervention for decreasing

CVD risk among women in menopausal transition in the setting of family medicine offices, at least early after diagnosing the risk and starting its management. Also, Cochrane blogshots may be a useful tool to structure health information so that it can be easily accessed and understood by patients.

Providing reminders about CVD risk and information about high-quality evidence about post-health risks in this study can be considered as a part of shared decision-making (SDM) process [27, 28], in which decision aids can help patients with some chronic diseases in lifestyle changes. In the linear regression model for a greater postintervention change in the 10-year CVD risk, the only significant variable was the higher score on the decisional conflict subscale *Effective decision*, which explained only 2.7% of variance and was a significant predictor only in the group that received only the reminder letters. It is difficult to interpret these results, which would indicate that higher scores on the *Effective decision* subscale, which means lower belief in one's own ability to complete tasks or one's own belief in the ability to make a good decision regarding the course of management, were more likely to reduce their CVD risk. Those participants may have come to the trial with lower effective decision skills, and the letters with reminders helped them increase those skills. Further studies are needed to explore the significance of this finding. A recent Cochrane systematic review showed that people exposed to decision aids are better informed and have a more active role in decision making, as well as accurate risk perception [29, 30]. The interventions such as sharing electronic health records (EHRs) may improve quality of care by providing patients with their personal health information, also involving them as key stakeholders in the self-management of their health and disease [31, 32]. In our study, doctors were the source of information for the patient. In other studies, health care providers have delegated preventive activities to practice nurses who work independently and have their own consultation. In the study by Laurant et al., experiences of chronic illness care in patients with established CVD or at high CVD risk did not change after the implementation of a tailored program aiming at nurses' counseling skills [33]. On the other hand, a Cochrane systematic review by Huntink et al. suggested that appropriately trained nurses can provide care of the same quality as primary care doctors and achieve similar health outcomes for patients [34]. While patient health outcomes were similar for nurses and doctors, patient satisfaction was higher with nurse-led care because nurses tended to provide longer consultations, give more information to patients, and recall patients more frequently than doctors. In the public health care system in Croatia and other similar systems in central

and Eastern Europe, where there are not enough nurses with relevant training [35], and where doctors still have the traditional central place in the healthcare system, family medicine doctors are still the best point of delivery of SDM information to the patient.

The prevention of CVD remains high on the agenda in health care systems, especially prevention based on shared-decision making, and the main goal of contemporary preventive medicine is therefore to encourage behavior change. However, while behavior change often seems easy in the short run, it can be difficult to sustain. Our study evaluated the short-term effects of an intervention to decrease CVD risks, but a recent systematic review [36] showed that the effects of lifestyle changes on the reduction in CVD risk factors reached their highest point at 12 months of follow-up and then gradually decreased over time. This may reflect the fact that the longer-term intervention may be more effective in reducing CVD risks but only if patients remain highly adherent to the interventions. As we showed in our study, the patients with higher risk and thus with better awareness about their status may benefit the most from being reminded about their CVD risk and potential interventions to alleviate it. Their health behavior can be influenced by a simple intervention, which is easily applicable in the primary care setting, as well as in low-resource economic settings.

## Conclusions

We showed that a simple method of reminding patients about their CVD risk and providing high-quality evidence in the form of Cochrane blogshots may be effective in the short-term reduction of the CVD risk. This can be a significant step in achieving sustainable lifestyle change in patients with high CVD risk and a contribution to the growing need for a more active participation of patients and a better understanding of their own health risks. Further research is required to assess the impact of CVD reminders to patients in larger population-based studies with longer follow-ups, cost-effectiveness and acceptability of different models of health service delivery, influence on the decision-making process, and the potential added value of providing high-quality evidence about health interventions.

## Abbreviations

ACC/AHA: American College of Cardiology/American Heart Association; BMI: Body mass index; CI(s): Confidence interval(s); CVD(s): Cardiovascular disease(s); DCS: Decisional Conflict Scale; EHR(s): Electronic health record(s); FTP: Future time perspective; GDPR: General Data Protection Regulation; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; NNT: Number needed to treat; RCT: Randomized controlled trial; SDM: Shared decision-making.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12916-022-02555-2>.

**Additional file 1.** Letter 1. The first letter sent to all trial participants (control group and intervention groups) (in Croatian). Letter 2. The letter containing the reminder about the CVD risk, sent to the passive intervention group (in Croatian). Letter 3. The letter containing the reminder about the CVD risk and the blogshot about the effect of calcium in the prevention of high blood pressure, sent to the active intervention group (in Croatian). Letter 4. The letter containing the reminder about the CVD risk and the blogshot about the effect of effects of reducing saturated fat acids on the risk of CVD, sent to the active intervention group (in Croatian). Letter 5. The letter containing the reminder about the CVD risk and the blogshot about the effect of green and black tea on the prevention of CVD, sent to the active intervention group (in Croatian).

**Additional file 2.** Demographic questionnaire for trial participants (in Croatian).

**Additional file 3: Table S1.** Comparison between CVD risks related variables (median, 95% confidence interval) between three groups before and after intervention.

## Acknowledgements

We thank the women who participated in the study.

## Authors' contributions

This study is a part of SJP's doctoral thesis. AM is SJP's academic supervisor. SJP, IB, MM, and AM conceived the study and prepared the study protocol. SJP coordinated the study. SJP, DB, NMD, TP, MĆ, IP and ŽV acquired the data. IB, SJP, and AM analyzed the data. All authors contributed to the interpretation of the study results. SJP wrote the manuscript draft, and all other authors contributed to the critical revision of the manuscript. All authors read and approved the final manuscript. All authors take accountability for the manuscript and the study.

## Funding

This study was funded by the Croatian Science Foundation ("Professionalism in Health - Decision making in practice and research, ProDeM") under Grant Agreement No. IP-2019-04-4882. The funder had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit results.

## Availability of data and materials

The data obtained and used in this study are available from the corresponding author upon reasonable request.

## Declarations

### Ethics approval and consent to participate

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional guidelines on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. The Ethics Committee of the University of Split, School of Medicine, approved the study, No. 2181-198-03-94/10-11-0038 and No. 2181-198-03-04/19-0044. Written informed consent was obtained from all participants after they received the information about the study.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Pulmonary Diseases, University of Split Hospital Center, Spinčićeva 1, Split, Croatia. <sup>2</sup>Department of Research in Biomedicine and Health and Center for Evidence-based Medicine, University of Split School

of Medicine, Šoltanska 2, Split, Croatia. <sup>3</sup>Department of Abdominal Surgery, University of Split Hospital Center, Spinčičeva 1, Split, Croatia. <sup>4</sup>Department of Family Medicine, University of Split School of Medicine, Šoltanska 2, Split, Croatia. <sup>5</sup>Family Practice Office, Kutina, Croatia. <sup>6</sup>Family Practice Office, Health Center of the Osijek-Baranja County, Osijek, Croatia. <sup>7</sup>Department of Family Medicine, JJ Strossmayer University School of Medicine, Osijek, Croatia. <sup>8</sup>Family Practice Office, Bijelo Brdo, Croatia. <sup>9</sup>University of Split, Ulica Ruđera Boškovića 31, 21000 Split, Croatia.

Received: 13 April 2022 Accepted: 6 September 2022

Published online: 20 October 2022

## References

- Buljan I, Tokalic R, Roguljic M, Zakarija-Grkovic I, Vrdoljak D, Milic P, et al. Comparison of blogshots with plain language summaries of Cochrane systematic reviews: a qualitative study and randomized trial. *Trials*. 2020;21(1):426. <https://doi.org/10.1186/s13063-020-04360-9>.
- Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular disease mortality in Europe. *Eur Heart J*. 1997;18(12):1231–48.
- Ijzelenberg W, Hellemans IM, van Tulder MW, Heymans MW, Rauwerda JA, van Rossum AC, et al. The effect of a comprehensive lifestyle intervention on cardiovascular risk factors in pharmacologically treated patients with stable cardiovascular disease compared to usual care: a randomized controlled trial. *BMC Cardiovasc Disord*. 2012;12:17. <https://doi.org/10.1186/1471-2261-12-71>.
- Gracia M, Mulvagh SL, Merz CNB, Burnig JE, Manson JE. Cardiovascular disease in women: clinical perspectives. *Circ Res*. 2016;118(8):1273–93. <https://doi.org/10.1161/CIRCRESAHA.116.307547>.
- Hilleary RS, Jabusch SA, Zheng B, Jirutek MR, Carter CA. Gender disparities in patient education provided during patient visits with a diagnosis of coronary heart disease. *Womens Health (Lond)*. 2019;15. <https://doi.org/10.1177/1745506519845591>.
- Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. *Circulation*. 2005;111(4):499–510. <https://doi.org/10.1161/01.CIR.0000154568.43333.82>.
- Shah T, Palaskas N, Ahmed A. An update on gender disparities in coronary heart disease care. *Curr Atheroscler Rep*. 2016;18(5):28. <https://doi.org/10.1007/s11883-016-0574-5>.
- Hayes SN. Preventing cardiovascular disease in women. *Am Fam Physician*. 2006;74(8):1331–40.
- Smiley WH 3rd. Getting patients to their lipid targets: a practical approach to implementing therapeutic lifestyle changes. *J Am Osteopath Assoc*. 2011;111(4 Suppl 3):eS13–7.
- Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL. The Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2016;37(29):2315–81. <https://doi.org/10.1093/eurheartj/ehw106>.
- McAlister FA, Stewart S, Ferrua S, McMurray JJJV. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. *J Am Coll Cardiol*. 2004;44(4):810–9. <https://doi.org/10.1016/j.jacc.2004.05.055>.
- Hansen L, Young RS, Hinami K, Leung A, Williams MV. Interventions to reduce 30-day rehospitalization: a systematic review. *Ann Intern Med*. 2011;155(8):520–8. <https://doi.org/10.7326/0003-4819-155-8-201110180-00008>.
- Guo Y, Chen Y, Lane DA, Liu L, Wang Y, Lip GYH. Mobile Health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAF app trial. *Am J Med*. 2017;130(12):1388–1396.e6. <https://doi.org/10.1016/j.amjmed.2017.07.003> Epub 2017 Aug 26.
- Grønning K, Lim S, Bratås O. Health status and self-management in patients with inflammatory arthritis—a five-year follow-up study after nurse-led patient education. *Nurs Open*. 2019;7(1):326–33. <https://doi.org/10.1002/nop2.394>.
- El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al. American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. *Circulation*. 2020;142(25):e506–32. <https://doi.org/10.1161/CIR.0000000000000912> Epub 2020 Nov 30.
- Cormick G, Ciapponi A, Cafferata ML, Belizan JM. Calcium supplementation for primary hypertension. *Cochrane Database Syst Rev*. 2015;2015(6):CD010037. <https://doi.org/10.1002/14651858.CD010037.pub2>.
- Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database Syst Rev*. 2020;5(5):CD011737. <https://doi.org/10.1002/14651858.CD011737.pub2>.
- Hartley L, Flowers N, Holmes J, Clarke A, Stranges S, Hooper L, et al. Green and black tea for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2013;2013(6):CD009934. <https://doi.org/10.1002/14651858.CD009934.pub2>.
- Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S49–73. <https://doi.org/10.1161/01.cir.0000437741.48606.98>.
- O'Connor AM. User manual – Decisional Conflict Scale. Ottawa: Ottawa Hospital Research Institute. 1993; updated 2010. [https://decisionaid.ohri.ca/docs/develop/User\\_Manuals/UM\\_Decisional\\_Conflict.pdf](https://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf). Accessed: 15 July 2022.
- O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making*. 1995;15(1):25–30. <https://doi.org/10.1177/0272989X9501500105>.
- Pavlicevic I, Skrabic S, Malicki M, Mercep AH, Marusic M, Marusic A. Decisional conflict and vaccine uptake: cross-sectional study of 2012/2013 influenza season in Croatia. *Arch Med Sci*. 2015;11(4):788–95. <https://doi.org/10.5114/aoms.2015.53299>.
- Zimbaro PG, Boyd JN. Putting time in perspective: a valid, reliable individual-differences metric. *J Pers Soc Psychol*. 1999;77(6):1271–88. <https://doi.org/10.1037/0022-3514.77.6.1271>.
- McClure JB, Divine G, Alexander G, Tolsma D, Rolnick SJ, Stopponi M, et al. (2009) A comparison of smokers' and nonsmokers' fruit and vegetable intake and relevant psychosocial factors. *Behav Med*. 2009;35(1):14–22. <https://doi.org/10.3200/BMED.35.1.14-22>.
- Karacic J, Dondio P, Buljan I, Hren D, Marusic A. Languages for different health information readers: multitrait-multimethod content analysis of Cochrane systematic reviews textual summary formats. *BMC Med Res Methodol*. 2019;19(1):75. <https://doi.org/10.1186/s12874-019-0716-x>.
- Buljan I, Malicki M, Wager E, Puljak L, Hren D, Kellie F, et al. No difference in knowledge obtained from infographic or plain language summary of a Cochrane systematic review: three randomized controlled trials. *J Clin Epidemiol*. 2018;97:86–94. <https://doi.org/10.1016/j.jclinepi.2017.12.003>.
- Bris P, Rimer B, Reilley B, Coates RC, Lee NC, Mullen P, et al. Promoting informed decisions about cancer screening in communities and health-care systems. *Am J Prev Med*. 2004;26(1):67–80. <https://doi.org/10.1016/j.amepre.2003.09.012>.
- Desroches S, Gagnon MP, Tapp S, Legere F. Implementing shared decision-making in nutrition clinical practice: a theory-based approach and feasibility study. *Implement Sci*. 2008;3:48. <https://doi.org/10.1186/1748-5908-3-48>.
- Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev*. 2014;2014(4):CD007768. <https://doi.org/10.1002/14651858.CD007768.pub3>.
- Stacey D, Legere F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2017;4(4):CD001431. <https://doi.org/10.1002/14651858.CD001431.pub5>.
- Neves AL, Freise L, Laranjo L, Carter AW, Darzi A, Mayer E. Impact of providing patients access to electronic health records on quality and safety of care: a systematic review and meta-analysis. *BMJ Qual Saf*. 2020;29(12):1019–32. <https://doi.org/10.1136/bmjqs-2019-010581>.

32. Dickey LL. Promoting preventive care with patient-held minirecords: a review. *Patient Educ Couns.* 1993;20(1):37–47. [https://doi.org/10.1016/0738-3991\(93\)90115-d](https://doi.org/10.1016/0738-3991(93)90115-d).
33. Laurant M, van der Biezen M, Wijers N, Watananirun K, Kontopantelis E, van Vught AJ. Substitution of doctors by nurses in primary care. *Cochrane Database Syst Rev.* 2018;7(7):CD001271. <https://doi.org/10.1002/14651858.CD001271.pub3>.
34. Huntink E, Koetsenruijter J, Wensing M, van Lieshout J. Patient cardiovascular risk self-management: results from a randomized trial of motivational interviewing delivered by practice nurses. *Fam Pract.* 2019;36(4):460–6. <https://doi.org/10.1093/fampra/cmz087>.
35. Bokan I, Buljan I, Marusic M, Malicki M, Marusic M. Predictors of academic success and aspirations in secondary nursing education: a cross-sectional study in Croatia. *Nurse Educ Today.* 2020;88:104370. <https://doi.org/10.1016/j.nedt.2020.104370>.
36. Zhang X, Delvin HM, Smith B, Imperatore G, Thomas W, Lobelo F, et al. Effect of lifestyle interventions on cardiovascular risk factors among adults without impaired glucose tolerance or diabetes: a systematic review and meta-analysis. *PLoS One.* 2017;12(5):e0176436. <https://doi.org/10.1371/journal.pone.0176436>.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

